-+ 0.00%
-+ 0.00%
-+ 0.00%

ARGENX SE - TO ADD FB102, FIRST-IN-CLASS ANTI-CD122 ANTIBODY, TO IMMUNOLOGY PORTFOLIO

Reuters·07/27/2026 05:00:00

Please log in to view news